| 0.28 -0.055 (-16.42%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.41 |
1-year : | 0.46 |
| Resists | First : | 0.35 |
Second : | 0.4 |
| Pivot price | 0.32 |
|||
| Supports | First : | 0.28 |
Second : | 0.23 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.32 |
| MA(100) : | 0.37 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 26.1 |
D(3) : | 35.8 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 9.18 | Low : | 0.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CURX ] has closed below the lower bollinger band by 14.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CURX ] is to continue within current trading range. It is unclear right now based on current values. 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.34 - 0.34 | 0.34 - 0.34 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.33 - 0.34 | 0.34 - 0.34 |
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Thu, 18 Jun 2026
Curanex Pharmaceuticals (NASDAQ: CURX) approves 5.7M‑share plan and 1:10–1:50 reverse split - Stock Titan
Tue, 16 Jun 2026
Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Thu, 07 May 2026
Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance - Investing.com
Thu, 16 Apr 2026
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX - Business Wire
Fri, 12 Sep 2025
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters - Yahoo Finance
Wed, 27 Aug 2025
Curanex Pharmaceuticals (CURX) Stock Price, News & Analysis - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 67.8 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 137 (K) |
| Shares Short P.Month | 115 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.1 % |
| Return on Equity (ttm) | -85.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -14 |
| PEG Ratio | 0 |
| Price to Book value | 28 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|